Alkeus Pharmaceuticals Reports Topline Results from SAGA Trial of Gildeuretinol (ALK-001) for Geographic Atrophy Secondary to Age-Related Macular Degeneration
Shots:
- The SAGA trial assessed safety, PK, tolerability & efficacy of gildeuretinol (oral) vs PBO for treating patients (n=198) with GA secondary to AMD, with 1EP as growth rate of GA lesions & 2EP as change in LLVA after 24mos.
- Study depicted a reduced GA lesion growth by 15.3% from 6 to 24mos., a significant visual improvement, with 4.4 fewer letters lost in LLVA over 24mos., slowed GA growth by 13.4% and a trend toward functional benefit in BCVA, with 3.3 fewer letters lost
- Safety profile was favorable & tolerable, aligning with previous Stargardt disease studies. 11% vs 44% of those at risk of CNV or wet AMD experienced AEs
Ref: Alkeus | Image: Alkeus
Related News:- Roche Reports 1-Year Data from P-IV (ELEVATUM) Study of Vabysmo (Faricimab) in Patients with Diabetic Macular Edema (DME)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
